Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
BATON ROUGE, La., Nov. 13, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, today releases the latest data updating the progression results at 19 weeks for all 20 patients, who have completed 6 vaccines in their Phase 1 clinical trial of ProscaVax for recurrent prostate cancer patients with increasing prostate specific antigen (PSA). ProscaVax is OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
All 20 patients enrolled in the trial completed ProscaVax therapy per protocol and have now completed the first follow-up at 19 weeks. 16 of 20 patients (80%) demonstrated stable disease/no prostate cancer progression. Only four patients progressed during ProscaVax therapy (3 PSA progression, 1 radiological progression in the brain).
The safety review confirmed there were no drug-related serious adverse events or dose-limiting toxicities resulting from the vaccine therapy.
OncBioMune is awaiting additional follow-up data related to our previously disclosed study data. This includes additional results on patients beyond the previously reported 12 of 15 patients that received ProscaVax vaccine, who exhibited an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay. Also, additional results on the 6 patients vaccinated after OncBioMune previously reported that 9 of 14 patients who received six ProscaVax vaccinations demonstrated increased PSA doubling times. Additional follow-up will provide longer follow-up intervals for the last six patients who completed the vaccine therapy.
“All the data to date is consistent with previous study data showing ProscaVax elicits immune responses to fight tumor growth in prostate cancer,” said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “We are impressed that 80 percent of the patients treated with ProscaVax demonstrated stable disease. We look forward to continuing to follow the patients in this study to collect additional data and also to conducting a larger study to further validate the therapeutic benefit of our vaccine platform technology.”
Contact:
Andrew Kucharchuk
225 227 2384
[email protected]
